Accessibility Menu
Enlivex Therapeutics logo

Enlivex Therapeutics(NASDAQ) ENLV

Current Price$4.71
Market Cap$77.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-97%
5 Year-96%
1 Year-74%
1 Month-51%
Enlivex Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.592026-07-22
Enlivex Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.49%USD 5.842026-07-15
1 month-50.94%USD 9.352026-06-22
3 month-66.29%USD 13.602026-04-23
Year to date-56.53%USD 10.552025-12-31
1 year-74.1%USD 17.702025-07-22
3 year-87.57%USD 36.902023-07-21
5 year-95.89%USD 111.602021-07-23
Since inception-97.03%USD 154.472019-03-26

Enlivex Therapeutics Financials at a Glance

Market Cap

$77.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$1.24B

EPS (TTM)

$382.12

P/E Ratio

0.01

Dividend

$0.00

Beta (Volatility)

0.85 (Low)

Price

$4.71

Volume

0

Open

$4.70

Previous Close

$4.71

Daily Range

$4.59 - $4.76

52-Week Range

$4.25 - $31.50

Estimated Earnings Date

Sep 4, 2026

ENLV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is a biopharmaceutical company focused on developing innovative immunotherapy treatments. The company utilizes its proprietary Allocetra™ platform to address immune system dysfunctions, targeting conditions such as sepsis, oncology, and COVID-19. Through strategic partnerships and a robust intellectual property portfolio, Enlivex aims to advance its pipeline and bring novel therapies to market.

Products and Services

Allocetra™: A cell therapy platform designed to restore immune balance.

Pipeline: Diverse range of therapies targeting immune-related conditions.

What Makes Enlivex Therapeutics Ltd. Special

Enlivex sets itself apart with its Allocetra™ platform, offering a unique approach to immune system modulation. Its focus on restoring rather than merely supplementing immune function provides a versatile treatment solution. Backed by experienced leadership and a comprehensive intellectual property strategy, Enlivex holds a strong competitive position in the biotech sector.

Five Things You Need to Know

Enlivex leverages the unique Allocetra™ platform for immune therapies.

The company targets life-threatening conditions like sepsis and COVID-19.

It emphasizes strategic partnerships to enhance clinical applications.

Enlivex maintains a robust intellectual property portfolio.

The leadership team has a proven track record in biopharmaceuticals.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

34

CEO

Oren Hershkovitz, PhD

Website

www.enlivex.com

Headquarters

Ness Ziona, TA 7403618, IL

ENLV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

248.08%

Return on Capital

-0.77%

Return on Assets

53.10%

Earnings Yield

100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$77.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

16.83M

Volume

0

Avg. Volume

38.84K

Financials (TTM)

Gross Profit

-$332.00K

Operating Income

-$15.03M

EBITDA

-$14.32M

Operating Cash Flow

-$10.69M

Capital Expenditure

-$71.94K

Free Cash Flow

-$11.09M

Cash & ST Invst.

$5.87M

Total Debt

$641.00K

Enlivex Therapeutics Performance Analysis

Enlivex Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Enlivex Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Enlivex Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -25.33108.4%
20232023-12-31USD -23.47-7.3%
20242024-12-31USD -10.98-53.2%
20252025-12-31USD 382.13N/A
Enlivex Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3133.3%
Q22025-06-3051.3%
Q32025-09-30-17.9%
Q42025-12-3128132.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$76.00K

-111.1%

Gross Margin

0.00%

N/A

Market Cap

$77.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.27M

N/A

Employees

34

N/A

Net Income

$1.24B

+24115.7%

EBITDA

-$5.79M

-12.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$5.87M

-75.1%

Total Debt

$641.00K

+20.0%

Accounts Receivable

$235.00K

-82.0%

Inventory

$0.00

N/A

Long Term Debt

$383.00K

+28.1%

Short Term Debt

$258.00K

+9.8%

Return on Assets

53.10%

N/A

Return on Invested Capital

-0.65%

N/A

Free Cash Flow

-$2.91M

+29.3%

Operating Cash Flow

-$2.90M

+28.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LSTALisata Therapeutics, Inc.
$2.20-1.79%
NRSNNeuroSense Therapeutics Ltd.
$0.65-7.14%
PASGPassage Bio, Inc.
$4.92+0.20%
GDTCCytoMed Therapeutics Limited
$0.96-1.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%
AALAmerican Airlines Group
$14.79-0.03%

Questions About ENLV

What is the current price of Enlivex Therapeutics?

Enlivex Therapeutics is trading at $4.71 per share.

What is the 52-week range for Enlivex Therapeutics?

Over the past 52 weeks, Enlivex Therapeutics has traded between $4.25 and $31.50.

How much debt does Enlivex Therapeutics have?

As of the most recent reporting period, Enlivex Therapeutics reported total debt of $641.00K.

How much cash does Enlivex Therapeutics have on hand?

Enlivex Therapeutics reported $2.01M in cash and cash equivalents in its most recent financial results.

What is Enlivex Therapeutics’s dividend yield?

Enlivex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services